RT Journal Article SR Electronic T1 How vaccination and contact isolation might interact to suppress transmission of Covid-19: a DCM study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.01.03.20248972 DO 10.1101/2021.01.03.20248972 A1 Karl J. Friston A1 Anthony Costello A1 Guillaume Flandin A1 Adeel Razi YR 2021 UL http://medrxiv.org/content/early/2021/01/04/2021.01.03.20248972.abstract AB This report describes a dynamic causal model that could be used to address questions about the rollout and efficacy of vaccines in the United Kingdom. For example, is suppression of community transmission a realistic aspiration? And, if not, what kind of endemic equilibrium might be achieved? What percentage of the population needs to be vaccinated? And over what timescale? It focuses on the synergies among (i) vaccination, (ii) the supported isolation of contacts of confirmed cases and (iii) restrictions on contact rates (i.e., lockdown and social distancing). To model these mitigations, we used a dynamic causal model that embeds an epidemiological model into agent-based behavioural model. The model structure and parameters were optimised to best explain responses—to the first and subsequent waves—enabling predictions over the forthcoming year under counterfactual scenarios. Illustrative analyses suggest that the full potential of vaccination is realised by increasing the efficacy of contact tracing: for example, under idealised (best case) assumptions—of an effective vaccine and efficient isolation of infected pre-symptomatic cases— suppression of community transmission would require 50% herd immunity by vaccinating 22% by the end of 2021; i.e., 15 million people or about 50,000 per day. With no change in the isolation of contacts, 36% would require vaccination, i.e., 25 million people. These figures should not be read as estimates of the actual number of people requiring vaccination; however, they illustrate the potential of this kind of model to quantify interactions among public health interventions. We anticipate using this model in a few months—to estimate the average effectiveness of vaccines when more data become available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Wellcome Centre for Human Neuroimaging is supported by core funding from Wellcome [203147/Z/16/Z]. A.R. is funded by the Australian Research Council (Refs: DE170100128 and DP200100757) and Australian National Health and Medical Research Council Investigator Grant(Ref: 1194910).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCLAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data used is from publically available database